Coegin Pharma AB (NGM: COEGIN)
Sweden
· Delayed Price · Currency is SEK 3.990
+0.090 (2.31%)
At close: Nov 18, 2024
Coegin Pharma AB Statistics
Total Valuation
Coegin Pharma AB has a market cap or net worth of SEK 83.18 million. The enterprise value is 69.41 million.
| Market Cap | 83.18M |
| Enterprise Value | 69.41M |
Important Dates
The next estimated earnings date is Friday, November 22, 2024.
| Earnings Date | Nov 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Coegin Pharma AB has 20.39 million shares outstanding. The number of shares has increased by 55.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 20.39M |
| Shares Change (YoY) | +55.41% |
| Shares Change (QoQ) | +89.01% |
| Owned by Insiders (%) | 0.81% |
| Owned by Institutions (%) | 3.58% |
| Float | 18.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.85 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.67 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.52
| Current Ratio | 16.52 |
| Quick Ratio | 16.28 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -67.22 |
Financial Efficiency
Return on equity (ROE) is -120.00% and return on invested capital (ROIC) is -73.67%.
| Return on Equity (ROE) | -120.00% |
| Return on Assets (ROA) | -68.22% |
| Return on Capital (ROIC) | -73.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -26.01M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.27% |
| 50-Day Moving Average | 4.35 |
| 200-Day Moving Average | 4.77 |
| Relative Strength Index (RSI) | 44.06 |
| Average Volume (20 Days) | 24,565 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -16,000 |
| Operating Income | -25.55M |
| Pretax Income | -26.01M |
| Net Income | -26.01M |
| EBITDA | -22.53M |
| EBIT | -25.55M |
| Earnings Per Share (EPS) | -2.09 |
Balance Sheet
| Cash & Cash Equivalents | 13.77M |
| Total Debt | n/a |
| Net Cash | 13.77M |
| Net Cash Per Share | 0.68 |
| Equity (Book Value) | 21.59M |
| Book Value Per Share | 1.06 |
| Working Capital | 13.88M |
Cash Flow
| Operating Cash Flow | -22.45M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Coegin Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -55.41% |
| Shareholder Yield | -55.41% |
| Earnings Yield | -51.31% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on June 15, 2023. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jun 15, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |